LITTELFUSE INC /DE — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LITTELFUSE INC /DE filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 28, 2013 | $757.85M | Jul 23, 2014 |
| FY2013 | Dec 29, 2012 | $667.91M | Jul 23, 2014 |
| FY2013 | Dec 31, 2011 | $664.96M | Jul 23, 2014 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $304.85M | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $317.89M | Feb 23, 2018 |
| FY2017 | Jul 1, 2017 | $313.36M | Feb 23, 2018 |
| FY2017 | Apr 1, 2017 | $285.44M | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $284.52M | Feb 23, 2018 |
| FY2017 | Oct 1, 2016 | $280.33M | Feb 23, 2018 |
| FY2017 | Jul 2, 2016 | $271.91M | Feb 23, 2018 |
| FY2017 | Apr 2, 2016 | $219.40M | Feb 23, 2018 |
| FY2016 | Jan 2, 2016 | $220.02M | Feb 27, 2017 |
| FY2016 | Sep 26, 2015 | $215.51M | Feb 27, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $906.04M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $787.54M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $900.24M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.01B | Mar 13, 2025 |
| FY2021 | Jan 1, 2022 | $199.49M | Feb 17, 2022 |
| FY2021 | Sep 25, 2021 | $214.57M | Feb 17, 2022 |
| FY2021 | Jun 26, 2021 | $197.40M | Feb 17, 2022 |
| FY2021 | Mar 27, 2021 | $160.47M | Feb 17, 2022 |
| FY2021 | Dec 26, 2020 | $138.08M | Feb 17, 2022 |
| FY2021 | Sep 26, 2020 | $138.83M | Feb 17, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($71.70M) | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $100.19M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $259.49M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $373.31M | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $283.81M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $129.99M | Feb 16, 2023 |
| FY2016 | Dec 31, 2016 | $104.49M | Feb 27, 2017 |
| FY2015 | Jan 2, 2016 | $82.47M | Mar 1, 2016 |
| FY2014 | Dec 27, 2014 | $19.51M | Feb 24, 2015 |
| FY2014 | Sep 27, 2014 | $29.94M | Feb 24, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $37.53M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $158.78M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $360.86M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $500.83M | Mar 13, 2025 |
| FY2021 | Jan 1, 2022 | $92.80M | Feb 17, 2022 |
| FY2021 | Sep 25, 2021 | $120.11M | Feb 17, 2022 |
| FY2021 | Jun 26, 2021 | $96.26M | Feb 17, 2022 |
| FY2021 | Mar 27, 2021 | $76.48M | Feb 17, 2022 |
| FY2021 | Dec 26, 2020 | $65.01M | Feb 17, 2022 |
| FY2021 | Sep 26, 2020 | $64.56M | Feb 17, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $106.90M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $107.77M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $102.43M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $95.60M | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $65.94M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $52.54M | Feb 16, 2023 |
| FY2021 | Dec 28, 2019 | $80.00M | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $87.26M | Feb 18, 2021 |
| FY2019 | Dec 30, 2017 | $50.49M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $42.20M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $381.77M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $350.42M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $354.66M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $344.81M | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $275.46M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $204.51M | Feb 16, 2023 |
| FY2021 | Dec 28, 2019 | $220.45M | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $276.33M | Feb 18, 2021 |
| FY2019 | Dec 30, 2017 | $212.83M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $206.13M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $433.76M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $367.62M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $457.39M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $419.72M | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $373.34M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $258.03M | Feb 16, 2023 |
| FY2021 | Dec 28, 2019 | $245.33M | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $331.83M | Feb 18, 2021 |
| FY2019 | Dec 30, 2017 | $269.17M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $180.13M | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $67.64M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $75.88M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $86.19M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $104.34M | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $90.56M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $56.19M | Feb 16, 2023 |
| FY2021 | Dec 28, 2019 | $61.90M | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $74.75M | Feb 18, 2021 |
| FY2019 | Dec 30, 2017 | $65.93M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $46.23M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $3.96B | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $3.89B | Feb 19, 2026 |
| FY2024 | Dec 30, 2023 | $4.00B | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.90B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $3.15B | Feb 16, 2023 |
| FY2021 | Dec 26, 2020 | $2.75B | Feb 17, 2022 |
| FY2020 | Dec 28, 2019 | $2.56B | Feb 18, 2021 |
| FY2019 | Dec 29, 2018 | $2.61B | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | $1.74B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $1.49B | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.53B | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $1.48B | Feb 19, 2026 |
| FY2024 | Dec 30, 2023 | $1.51B | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.69B | Feb 16, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $2.43B | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $2.41B | Feb 19, 2026 |
| FY2024 | Dec 30, 2023 | $2.48B | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.21B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $1.89B | Feb 16, 2023 |
| FY2021 | Dec 26, 2020 | $1.61B | Feb 17, 2022 |
| FY2020 | Dec 28, 2019 | $1.50B | Feb 18, 2021 |
| FY2019 | Dec 29, 2018 | $1.48B | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | $927.42M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $814.79M | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.21B | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $1.23B | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $1.31B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.19B | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $929.79M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $816.81M | Feb 16, 2023 |
| FY2021 | Dec 28, 2019 | $820.59M | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $826.72M | Feb 18, 2021 |
| FY2019 | Dec 30, 2017 | $453.41M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $403.54M | Feb 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.67B | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $1.82B | Feb 19, 2026 |
| FY2024 | Dec 30, 2023 | $1.78B | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.59B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $1.27B | Feb 16, 2023 |
| FY2021 | Dec 26, 2020 | $1.03B | Feb 17, 2022 |
| FY2020 | Dec 28, 2019 | $950.90M | Feb 18, 2021 |
| FY2019 | Dec 29, 2018 | $856.51M | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | $722.14M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $634.39M | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $563.39M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $724.92M | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | $555.51M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $562.59M | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $478.47M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $687.53M | Feb 16, 2023 |
| FY2021 | Dec 28, 2019 | $531.14M | Feb 17, 2022 |
| FY2019 | Dec 29, 2018 | $489.73M | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | $429.68M | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $275.12M | Feb 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $802.63M | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | $856.11M | Feb 19, 2026 |
| FY2024 | Dec 30, 2023 | $871.94M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.00B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $636.90M | Feb 16, 2023 |
| FY2021 | Dec 26, 2020 | $687.03M | Feb 17, 2022 |
| FY2020 | Dec 28, 2019 | $679.16M | Feb 18, 2021 |
| FY2019 | Dec 29, 2018 | $694.73M | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | $495.61M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $454.14M | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | (2) | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | 10 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 15 | Mar 13, 2025 |
| FY2021 | Jan 1, 2022 | 2 | Feb 17, 2022 |
| FY2021 | Sep 25, 2021 | 3 | Feb 17, 2022 |
| FY2021 | Jun 26, 2021 | 3 | Feb 17, 2022 |
| FY2021 | Mar 27, 2021 | 2 | Feb 17, 2022 |
| FY2021 | Dec 26, 2020 | 2 | Feb 17, 2022 |
| FY2021 | Sep 26, 2020 | 2 | Feb 17, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | (2) | Feb 19, 2026 |
| FY2025 | Dec 28, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Dec 30, 2023 | 10 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 14 | Mar 13, 2025 |
| FY2021 | Jan 1, 2022 | 2 | Feb 17, 2022 |
| FY2021 | Sep 25, 2021 | 3 | Feb 17, 2022 |
| FY2021 | Jun 26, 2021 | 3 | Feb 17, 2022 |
| FY2021 | Mar 27, 2021 | 2 | Feb 17, 2022 |
| FY2021 | Dec 26, 2020 | 2 | Feb 17, 2022 |
| FY2021 | Sep 26, 2020 | 2 | Feb 17, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | 22.71M | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | 22.63M | Feb 23, 2018 |
| FY2016 | Jan 2, 2016 | 22.42M | Feb 27, 2017 |
| FY2015 | Dec 27, 2014 | 22.59M | Mar 1, 2016 |
| FY2014 | Dec 28, 2013 | 22.47M | Feb 24, 2015 |
| FY2013 | Dec 29, 2012 | 22.03M | Jul 23, 2014 |
| FY2012 | Dec 31, 2011 | 21.55M | Feb 27, 2013 |
| FY2011 | Jan 1, 2011 | 21.75M | Feb 24, 2012 |